BASAL CELL NAEVUS SYNDROME

BASAL CELL NAEVUS SYNDROME was reported 23 times

BASAL CELL NAEVUS SYNDROME is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Actinomycin [EPC] 6 0.0027
1 Hedgehog Pathway Inhibitor [EPC] 3 0.0003
2 Topoisomerase Inhibitor [EPC] 8 0.0001
3 Platinum-based Drug [EPC] 8 0.0000
4 Alkylating Drug [EPC] 7 0.0000
5 Interleukin-23 Antagonist [EPC] 2 0.0000
6 Interleukin-12 Antagonist [EPC] 1 0.0000
7 Serotonin-3 Receptor Antagonist [EPC] 1 0.0000
8 Janus Kinase Inhibitor [EPC] 1 0.0000
9 Estrogen [EPC] 1 0.0000
10 Tumor Necrosis Factor Blocker [EPC] 4 0.0000
11 HMG-CoA Reductase Inhibitor [EPC] 1 0.0000
12 Folate Analog Metabolic Inhibitor [EPC] 1 0.0000
13 Corticosteroid [EPC] 2 0.0000
14 Benzodiazepine [EPC] 1 0.0000
15 Nonsteroidal Anti-inflammatory Drug [EPC] 1 0.0000